Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 0.80 |
| ▸ | AURKA | O14965 | 6/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.54 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8557909 | 0.95 | BTK (0.72) | BTKAURKAPDPK1AURKBCKS1B | |
| SCHEMBL18780335 | 0.84 | BTK (0.70) | BTKAURKAPDPK1AURKBCKS1B | |
| SCHEMBL6115795 | 0.82 | BTK (0.54) | BTKAURKAPDPK1AURKBCKS1B | |
| SCHEMBL18759567 | 0.82 | BTK (0.55) | BTK | |
| SCHEMBL6115790 | 0.82 | BTK (0.81) | BTKAURKAPDPK1AURKB | |
| SCHEMBL8401448 | 0.82 | BTK (0.53) | BTK | |
| SCHEMBL6116095 | 0.81 | BTK (0.51) | BTK | |
| SCHEMBL18780324 | 0.80 | BTK (0.64) | BTKAURKAPDPK1AURKBCKS1B | |
| SCHEMBL6116106 | 0.80 | BTK (0.52) | BTK | |
| SCHEMBL8401526 | 0.80 | BTK (0.50) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789614-B1 | Azaindazoles as Btk kinase modulators and use thereof | BRISTOL MYERS SQUIBB CO (US) | 2017-04-26 | — | — | EP | claimed |
| EP-2789614-A1 | Azaindazoles as Btk kinase modulators and use thereof | Bristol-Myers Squibb Company (US) | 2014-10-15 | — | — | EP | claimed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | claimed |
| EP-2789614-B1 | Azaindazoles as Btk kinase modulators and use thereof | BRISTOL MYERS SQUIBB CO (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-2789614-B1 | Azaindazoles as Btk kinase modulators and use thereof | BRISTOL MYERS SQUIBB CO (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-2789614-A1 | Azaindazoles as Btk kinase modulators and use thereof | Bristol-Myers Squibb Company (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2789614-A1 | Azaindazoles as Btk kinase modulators and use thereof | Bristol-Myers Squibb Company (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BTK, ABL1, JAK1 | BTK 1/4885AURKA 123/4885PDPK1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.